Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 38

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 3
Chunk 38
---
 applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements
can be difficult to resolve if neither of the parties has final decision-making authority.

Collaborations with pharmaceutical
or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination
or expiration could adversely affect us financially and could harm our business reputation.

Our reliance on third parties requires us
to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated
or disclosed.

Because we rely on third parties
to develop and manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research
agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning
research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our
confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties, the need
to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors,
are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our
proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other
unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.

Risks Related to Our Intellectual Property

We have been granted several issued patents
and filed multiple patent applications. There can be no assurance that any of our patent applications will result in issued patents. As
a result, our ability to protect our proprietary technology in the marketplace may be limited.

We have been granted issued
patents in countries worldwide. These issued patents cover a range of areas including: the therapeutic use of mazindol for the treatment
of ADHD and combination therapies containing mazindol (add-ons with iron or stimulants) in sleep disorders such as narcolepsy or IH. We
have also filed patent applications in many countries worldwide. Unless and until our pending patent applications are issued, their protective
scope is impossible to determine. It is impossible to predict whether or how many of our patent applications will result in issued patents.
Even if pending applications are issued, they